Literature DB >> 27011345

Feasibility of using DNA-immobilized nanocellulose-based immunoadsorbent for systemic lupus erythematosus plasmapheresis.

Changgang Xu1, Daniel O Carlsson2, Albert Mihranyan3.   

Abstract

The goal of this project was to study the feasibility of using a DNA-immobilized nanocellulose-based immunoadsorbent for possible application in medical apheresis such as systemic lupus erythematosus (SLE) treatment. Calf thymus DNA was bound to high surface area nanocellulose membrane at varying concentrations using UV-irradiation. The DNA-immobilized samples were characterized with scanning electron microscopy, atomic force microscopy, and phosphorus elemental analysis. The anti-ds-DNA IgG binding was tested in vitro using ELISA. The produced sample showed high affinity in vitro to bind anti-ds-DNA-antibodies from mice, as much as 80% of added IgG was bound by the membrane. Furthermore, the binding efficiency was quantitatively dependent on the amount of immobilized DNA onto nanocellulose membrane. The described nanocellulose membranes are interesting immunoadsorbents for continued clinical studies.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune diseases; DNA immobilization; Immunoadsorption; Nanocellulose; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27011345     DOI: 10.1016/j.colsurfb.2016.03.014

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  2 in total

1.  Blood Compatibility of Sulfonated Cladophora Nanocellulose Beads.

Authors:  Igor Rocha; Jonas Lindh; Jaan Hong; Maria Strømme; Albert Mihranyan; Natalia Ferraz
Journal:  Molecules       Date:  2018-03-07       Impact factor: 4.411

2.  Blood purification in two patients with clinically amyopathic dermatomyositis associated with interstitial lung disease with anti-melanoma differentiation-associated gene-5 antibody (MDA-5).

Authors:  Han-Yu Shi; Xue-Ren Li; Lu-Qing Wei; Shou-Chun Peng
Journal:  Respir Med Case Rep       Date:  2019-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.